Canaccord Genuity Downgrades Neoleukin Therapeutics (NLTX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NLTX Hot Sheet
Price: $3.49 --0%
Rating Summary:
2 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
2 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Canaccord Genuity analyst William Maughan downgraded Neoleukin Therapeutics (NASDAQ: NLTX) from Buy to Hold with a price target of $1.00 (from $10.00).
For an analyst ratings summary and ratings history on Neoleukin Therapeutics click here. For more ratings news on Neoleukin Therapeutics click here.
Shares of Neoleukin Therapeutics closed at $0.53 yesterday.
You May Also Be Interested In
- Insulet Corporation (PODD) PT Raised to $163 at TD Cowen
- Uber Inc. (UBER) PT Lowered to $90 at BTIG
- Flutter Entertainment (FLUT) PT Lowered to $160 at Jefferies
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
